AAA
SGMT icon

Affinity Asset Advisors’s Sagimet Biosciences SGMT Stock Holding History

Affinity Asset Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Buy
2,497,864
+1,629,844
+188% +$11.1M 0.87% 36
2026
Q1 		$4.54M Sell
868,020
-280,225
-24% -$1.56M 0.23% 72
2025
Q4 		$6.8M Buy
1,148,245
+798,245
+228% +$5.74M 0.39% 54
2025
Q3 		$2.4M Buy
+350,000
New +$2.84M 0.21% 72

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Affinity Asset Advisors's SGMT Position: Q2 2026 in Review

Affinity Asset Advisors increased its Sagimet Biosciences (SGMT) stake by 188% in Q2 2026, buying an estimated $11.1M and bringing the position to 2,497,864 shares worth $19.3M. The position accounts for 0.87% of the portfolio, ranked #36.

Affinity Asset Advisors first reported a position in SGMT in Q3 2025 and has held it in 4 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Affinity Asset Advisors held 2,497,864 shares of Sagimet Biosciences worth $19.3M as of Q2 2026.
  • Affinity Asset Advisors bought 1,629,844 Sagimet Biosciences shares in Q2 2026, an estimated $11.1M.
  • Sagimet Biosciences made up 0.87% of Affinity Asset Advisors's portfolio in Q2 2026, its #36 holding.
  • Affinity Asset Advisors first reported a position in Sagimet Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.